Search

Your search keyword '"Rossetti L."' showing total 977 results
Start Over Author "Rossetti L."
977 results on '"Rossetti L."'

2. Treatment of Open-Angle Glaucoma and Ocular Hypertension with the Fixed-Dose Combination of Preservative-Free Tafluprost/Timolol: Clinical Outcomes from Ophthalmology Clinics in Italy

Author

Oddone F, Scorcia V, Iester M, Sisto D, De Cilla S, Bettin P, Cagini C, Figus M, Marchini G, Rossetti L, Rossi G, Salgarello T, Scuderi GL, and Staurenghi G

Subjects
fixed-dose combination therapy, intraocular pressure, ocular hypertension, pf tafluprost/timolol fc, preservative-free topical medication, primary open-angle glaucoma, Ophthalmology, RE1-994
Abstract

Francesco Oddone,1 Vincenzo Scorcia,2 Michele Iester,3 Dario Sisto,4 Stefano De Cilla,5 Paolo Bettin,6 Carlo Cagini,7 Michele Figus,8 Giorgio Marchini,9 Luca Rossetti,10 Gemma Rossi,11 Tommaso Salgarello,12,13 Gian Luca Scuderi,14 Giovanni Staurenghi15 On behalf of the VISIONARY Study Group (Italy)1Glaucoma Unit, IRCSS-Fondazione Bietti, Roma, Italy; 2Department of Ophthalmology, University Magna Græcia of Catanzaro, Catanzaro, Italy; 3Eye Clinic of Genoa, Department of Neuroscience, Rehabilitation, Ophthalmology, Genetics, Maternal and Child Health (DiNOGMI), University of Genova, Genova, Italy; 4Ophthalmology Department, University of Bari, Bari, Italy; 5Department of Health Sciences, Eye Clinic, University of Piemonte Orientale, Novara, Italy; 6Department of Ophthalmology, IRCCS San Raffaele Scientific Institute, Vita-Salute San Raffaele University, Milano, Italy; 7Department of Medicine and Surgery, Ophthalmology Section, University of Perugia, Perugia, Italy; 8Ophthalmology, Department of Surgery, Medicine, Molecular and Emergency, University of Pisa, Pisa, Italy; 9Ophthalmology Unit, Department of Neurosciences, Biomedicine and Movement, University of Verona, Verona, Italy; 10Eye Clinic, San Paolo Hospital, University of Milan, Milano, Italy; 11University Eye Clinic, Fondazione IRCCS Policlinico S. Matteo, Pavia, Italy; 12Ophthalmology Unit, Department of Ageing, Neurosciences, Head-Neck and Orthopaedics Sciences, Fondazione Policlinico Universitario A. Gemelli IRCCS, Roma, Italy; 13Institute of Ophthalmology, Università Cattolica del Sacro Cuore, Roma, Italy; 14NESMOS Department, Ophthalmology Unit, St. Andrea Hospital, Università di Roma La Sapienza, Roma, Italy; 15Eye Clinic, Department of Biomedical and Clinical Sciences Luigi Sacco, University of Milan, Milano, ItalyCorrespondence: Francesco Oddone, Glaucoma Unit, IRCSS-Fondazione Bietti, Roma, Italy, Tel + 39 06 85356727, Email oddonef@gmail.comIntroduction: The VISIONARY study examined the intraocular pressure (IOP)-lowering efficacy and tolerability of the preservative-free fixed-dose combination of tafluprost (0.0015%) and timolol (0.5%) (PF tafluprost/timolol FC) in a real-world setting. The country-level data reported herein comprise the largest and first observational study of PF tafluprost/timolol FC therapy in Italy.Methods: An observational, multicenter, prospective study included adult Italian patients with open-angle glaucoma (OAG) or ocular hypertension (OHT) demonstrating insufficient response or poor tolerability with topical prostaglandin analogue (PGA) or beta-blocker monotherapy. Treatment was switched to PF tafluprost/timolol FC therapy at baseline. Primary endpoint was the absolute mean IOP change from baseline at Month 6. Exploratory and safety endpoints included change in IOP at Weeks 4 and 12, ocular signs, symptom severity and reporting of adverse events (AEs).Results: Overall, 160 OAG/OHT patients were included. Mean ± standard deviation IOP was reduced from 19.6 ± 3.6 mmHg at baseline to 14.5 ± 2.6 mmHg at Month 6 (reduction of 5.1 ± 3.7 mmHg; 24.1%; p < 0.0001). IOP reduction was also statistically significant at Week 4 (23.1%; p < 0.0001) and Week 12 (24.7%; p < 0.0001). Based on data cutoff values for mean IOP change of ≥ 20%, ≥ 25%, ≥ 30% and ≥ 35%, respective Month 6 responder rates were 68.1%, 48.7%, 36.2% and 26.9%. Most ocular signs and symptoms were significantly reduced in severity from baseline at Month 6. Two non-serious and mild AEs were reported during the study period, among which, one AE was treatment-related (eyelash growth). &#x2003Conclusion: Italian OAG and OHT patients demonstrated a significant IOP reduction from baseline at Week 4 that was maintained over a 6-month period following a switch from topical PGA or beta-blocker monotherapy to PF tafluprost/timolol FC therapy. Severity of most ocular signs and symptoms was significantly reduced during the study period, and PF tafluprost/timolol FC was generally well tolerated.Keywords: fixed-dose combination therapy, intraocular pressure, ocular hypertension, PF tafluprost/timolol FC, preservative-free topical medication, primary open-angle glaucoma

Published
2022

5. Efficacy and Safety of VisuEvo® and Cationorm® for the Treatment of Evaporative and Non-Evaporative Dry Eye Disease: A Multicenter, Double-Blind, Cross-Over, Randomized Clinical Trial

Author

Fogagnolo P, Quisisana C, Caretti A, Marchina D, Dei Cas M, Melardi E, and Rossetti L

Subjects
evaporative dry eye disease, tear break-up time (tbut), ocular surface disease index questionnaire, meibomian gland disturbance, glaucoma, ocular surface, Ophthalmology, RE1-994
Abstract

Paolo Fogagnolo,1 Chiara Quisisana,1 Anna Caretti,2 Daniele Marchina,1 Michele Dei Cas,2 Ettore Melardi,1 Luca Rossetti1 1Eye Clinic ASST Santi Paolo Carlo, Department of Health Sciences, San Paolo Hospital, University of Milan, Milan, Italy; 2Department of Health Sciences, Laboratory of Biochemistry, University of Milan, Milan, ItalyCorrespondence: Paolo FogagnoloEye Clinic ASST Santi Paolo Carlo, Department of Health Sciences, San Paolo Hospital, University of Milan, Via Di Rudinì 8, Milan 20142, ItalyTel +39 02 81844301Email paolo.fogagnolo@unimi.itPurpose: To compare the efficacy of the new lubricating product VisuEvo® (VSE) vs Cationorm® (CTN) in patients with dry eye disease (DED).Methods: Seventy-two patients with evaporative (n=54) and non-evaporative DED (n=18) were included in a multicenter, double-blind, 12-week cross-over study to receive VSE (6 weeks) and CTN (6 weeks) in randomized sequence. After baseline, two visits were performed during each period (intermediate and final visit, respectively at 2 and 6 weeks from the beginning of each period). Primary (tear break-up time, TBUT) and secondary endpoints (Schirmer I, Ferning, blink rate, osmometry, cytokine and lipid expression, ocular surface staining, patient satisfaction, and OSDI score) were compared.Results: Sixty-three patients were evaluated for efficacy and 68 patients for safety. The intergroup differences for mean TBUT values were not significant at any study visit (baseline 3.2 ± 1.5 sec; intermediate visits 4.5 ± 1.9 and 4.5 ± 1.8 sec in VSE and CTN groups, respectively, p = 0.10; final visits 5.4 ± 2.4 and 6.0 ± 3.1, respectively, p=0.63). Also, the assessment of secondary endpoints showed no significant difference between the two groups. The two study treatments were equally effective in evaporative and non-evaporative DED. The safety profile was excellent for both ocular treatments; transient blurred vision was observed in 11 patients only during CTN, 10 patients only during VSE, and 16 during both treatments.Conclusion: VSE was non-inferior to CTN in restoring tear film composition, increasing its stability and reducing ocular surface damage in evaporative and non-evaporative DED patients.Study Identifier: NCT03833882.Keywords: evaporative dry eye disease, tear break-up time, Ocular Surface Disease Index questionnaire, meibomian gland disturbance, glaucoma, ocular surface

Published
2020

12. Causes of blindness and vision impairment in 2020 and trends over 30 years, and prevalence of avoidable blindness in relation to VISION 2020: the Right to Sight: an analysis for the Global Burden of Disease Study

Author

Bourne R. R. A., Steinmetz J. D., Saylan M., Mersha A. M., Weldemariam A. H., Wondmeneh T. G., Sreeramareddy C. T., Pinheiro M., Yaseri M., Yu C., Zastrozhin M. S., Zastrozhina A., Zhang Z. -J., Zimsen S. R. M., Yonemoto N., Tsegaye G. W., Vu G. T., Vongpradith A., Renzaho A. M. N., Sorrie M. B., Shaheen A. A., Shiferaw W. S., Skryabin V. Y., Skryabina A. A., Saya G. K., Rahimi-Movaghar V., Shigematsu M., Sahraian M. A., Naderifar H., Sabour S., Rathi P., Sathian B., Miller T. R., Rezapour A., Rawal L., Pham H. Q., Parekh U., Podder V., Onwujekwe O. E., Pasovic M., Otstavnov N., Negash H., Pawar S., Naimzada M. D., Al Montasir A., Ogbo F. A., Owolabi M. O., Pakshir K., Mohammad Y., Moni M. A., Nunez-Samudio V., Mulaw G. F., Naveed M., Maleki S., Michalek I. M., Misra S., Swamy S. N., Mohammed J. A., Flaxman S., Park E. -C., Briant P. S., Meles G. G., Hayat K., Landires I., Kim G. R., Liu X., LeGrand K. E., Taylor H. R., Kunjathur S. M., Khoja T. A. M., Bicer B. K., Khalilov R., Hashi A., Kayode G. A., Carneiro V. L. A., Kavetskyy T., Kosen S., Kulkarni V., Holla R., Kalhor R., Jayaram S., Islam S. M. S., Gilani S. A., Eskandarieh S., Molla M. D., Itumalla R., Farzadfar F., Congdon N. G., Elhabashy H. R., Elayedath R., Couto R. A. S., Dervenis N., Cromwell E. A., Dahlawi S. M. A., Resnikoff S., Casson R. J., Abdoli A., Choi J. -Y. J., Dos Santos F. L. C., Abrha W. A., Nagaraja S. B., Abualhasan A., Adal T. G., Aregawi B. B., Beheshti M., Abu-Gharbieh E., Afshin A., Ahmadieh H., Alemzadeh S. A., Arrigo A., Atnafu D. D., Ashbaugh C., Ashrafi E., Alemayehu W., Alfaar A. S., Alipour V., Anbesu E. W., Androudi S., Arabloo J., Arditi A., Bagli E., Baig A. A., Barnighausen T. W., Battaglia Parodi M., Bhagavathula A. S., Bhardwaj N., Bhardwaj P., Bhattacharyya K., Bijani A., Bikbov M., Bottone M., Braithwaite T., Bron A. M., Butt Z. A., Cheng C. -Y., Chu D. -T., Cicinelli M. V., Coelho J. M., Dai X., Dana R., Dandona L., Dandona R., Del Monte M. A., Deva J. P., Diaz D., Djalalinia S., Dreer L. E., Ehrlich J. R., Ellwein L. B., Emamian M. H., Fernandes A. G., Fischer F., Friedman D. S., Furtado J. M., Gaidhane S., Gazzard G., Gebremichael B., George R., Ghashghaee A., Golechha M., Hamidi S., Hammond B. R., Hartnett M. E. R., Hartono R. K., Hay S. I., Heidari G., Ho H. C., Househ M., Ibitoye S. E., Ilic I. M., Huang J. J., Ilic M. D., Ingram A. D., Irvani S. S. N., Jha R. P., Kahloun R., Kandel H., Kasa A. S., Kempen J. H., Khairallah M., Khan E. A., Khanna R. C., Khatib M. N., Kim J. E., Kim Y. J., Kisa A., Kisa S., Koyanagi A., Kurmi O. P., Lansingh V. C., Leasher J. L., Leveziel N., Limburg H., Manafi N., Mansouri K., McAlinden C., Mohammadi S. F., Mokdad A. H., Morse A. R., Naderi M., Naidoo K. S., Nangia V., Nguyen H. L. T., Ogundimu K., Olagunju A. T., Panda-Jonas S., Pesudovs K., Peto T., Ur Rahman M. H., Ramulu P. Y., Rawaf D. L., Rawaf S., Reinig N., Robin A. L., Rossetti L., Safi S., Sahebkar A., Samy A. M., Serle J. B., Shaikh M. A., Shen T. T., Shibuya K., Shin J. I., Silva J. C., Silvester A., Singh J. A., Singhal D., Sitorus R. S., Skiadaresi E., Soheili A., Sousa R. A. R. C., Stambolian D., Tadesse E. G., Tahhan N., Tareque Md. I., Topouzis F., Tran B. X., Tsilimbaris M. K., Varma R., Virgili G., Wang N., Wang Y. X., West S. K., Wong T. Y., Jonas J. B., Vos T., Bourne, R. R. A., Steinmetz, J. D., Saylan, M., Mersha, A. M., Weldemariam, A. H., Wondmeneh, T. G., Sreeramareddy, C. T., Pinheiro, M., Yaseri, M., Yu, C., Zastrozhin, M. S., Zastrozhina, A., Zhang, Z. -J., Zimsen, S. R. M., Yonemoto, N., Tsegaye, G. W., Vu, G. T., Vongpradith, A., Renzaho, A. M. N., Sorrie, M. B., Shaheen, A. A., Shiferaw, W. S., Skryabin, V. Y., Skryabina, A. A., Saya, G. K., Rahimi-Movaghar, V., Shigematsu, M., Sahraian, M. A., Naderifar, H., Sabour, S., Rathi, P., Sathian, B., Miller, T. R., Rezapour, A., Rawal, L., Pham, H. Q., Parekh, U., Podder, V., Onwujekwe, O. E., Pasovic, M., Otstavnov, N., Negash, H., Pawar, S., Naimzada, M. D., Al Montasir, A., Ogbo, F. A., Owolabi, M. O., Pakshir, K., Mohammad, Y., Moni, M. A., Nunez-Samudio, V., Mulaw, G. F., Naveed, M., Maleki, S., Michalek, I. M., Misra, S., Swamy, S. N., Mohammed, J. A., Flaxman, S., Park, E. -C., Briant, P. S., Meles, G. G., Hayat, K., Landires, I., Kim, G. R., Liu, X., Legrand, K. E., Taylor, H. R., Kunjathur, S. M., Khoja, T. A. M., Bicer, B. K., Khalilov, R., Hashi, A., Kayode, G. A., Carneiro, V. L. A., Kavetskyy, T., Kosen, S., Kulkarni, V., Holla, R., Kalhor, R., Jayaram, S., Islam, S. M. S., Gilani, S. A., Eskandarieh, S., Molla, M. D., Itumalla, R., Farzadfar, F., Congdon, N. G., Elhabashy, H. R., Elayedath, R., Couto, R. A. S., Dervenis, N., Cromwell, E. A., Dahlawi, S. M. A., Resnikoff, S., Casson, R. J., Abdoli, A., Choi, J. -Y. J., Dos Santos, F. L. C., Abrha, W. A., Nagaraja, S. B., Abualhasan, A., Adal, T. G., Aregawi, B. B., Beheshti, M., Abu-Gharbieh, E., Afshin, A., Ahmadieh, H., Alemzadeh, S. A., Arrigo, A., Atnafu, D. D., Ashbaugh, C., Ashrafi, E., Alemayehu, W., Alfaar, A. S., Alipour, V., Anbesu, E. W., Androudi, S., Arabloo, J., Arditi, A., Bagli, E., Baig, A. A., Barnighausen, T. W., Battaglia Parodi, M., Bhagavathula, A. S., Bhardwaj, N., Bhardwaj, P., Bhattacharyya, K., Bijani, A., Bikbov, M., Bottone, M., Braithwaite, T., Bron, A. M., Butt, Z. A., Cheng, C. -Y., Chu, D. -T., Cicinelli, M. V., Coelho, J. M., Dai, X., Dana, R., Dandona, L., Dandona, R., Del Monte, M. A., Deva, J. P., Diaz, D., Djalalinia, S., Dreer, L. E., Ehrlich, J. R., Ellwein, L. B., Emamian, M. H., Fernandes, A. G., Fischer, F., Friedman, D. S., Furtado, J. M., Gaidhane, S., Gazzard, G., Gebremichael, B., George, R., Ghashghaee, A., Golechha, M., Hamidi, S., Hammond, B. R., Hartnett, M. E. R., Hartono, R. K., Hay, S. I., Heidari, G., Ho, H. C., Househ, M., Ibitoye, S. E., Ilic, I. M., Huang, J. J., Ilic, M. D., Ingram, A. D., Irvani, S. S. N., Jha, R. P., Kahloun, R., Kandel, H., Kasa, A. S., Kempen, J. H., Khairallah, M., Khan, E. A., Khanna, R. C., Khatib, M. N., Kim, J. E., Kim, Y. J., Kisa, A., Kisa, S., Koyanagi, A., Kurmi, O. P., Lansingh, V. C., Leasher, J. L., Leveziel, N., Limburg, H., Manafi, N., Mansouri, K., Mcalinden, C., Mohammadi, S. F., Mokdad, A. H., Morse, A. R., Naderi, M., Naidoo, K. S., Nangia, V., Nguyen, H. L. T., Ogundimu, K., Olagunju, A. T., Panda-Jonas, S., Pesudovs, K., Peto, T., Ur Rahman, M. H., Ramulu, P. Y., Rawaf, D. L., Rawaf, S., Reinig, N., Robin, A. L., Rossetti, L., Safi, S., Sahebkar, A., Samy, A. M., Serle, J. B., Shaikh, M. A., Shen, T. T., Shibuya, K., Shin, J. I., Silva, J. C., Silvester, A., Singh, J. A., Singhal, D., Sitorus, R. S., Skiadaresi, E., Soheili, A., Sousa, R. A. R. C., Stambolian, D., Tadesse, E. G., Tahhan, N., Tareque, Md. I., Topouzis, F., Tran, B. X., Tsilimbaris, M. K., Varma, R., Virgili, G., Wang, N., Wang, Y. X., West, S. K., Wong, T. Y., Jonas, J. B., Vos, T., University of Washington [Seattle], Anglia Ruskin University (ARU), Imperial College London, University of Melbourne, Heidelberg University, Jahrom University of Medical Sciences, Aksum University, Cairo University, University of Sharjah, Wolkite University, Shahid Beheshti University of Medical Sciences [Tehran] (SBUMS), Shahid Beheshti University, The Fred Hollows Foundation, Iran University of Medical Sciences, University of Leipzig Medical Center, University of Thessaly [Volos] (UTH), Visibility Metrics LLC, Adigrat University, San Raffaele Hospital, Tehran University of Medical Sciences (TUMS), Bahir Dar University (BDU), University Hospital of Ioannina, Sultan Zainal Abidin University, Universita Vita Salute San Raffaele = Vita-Salute San Raffaele University [Milan, Italie] (UniSR), Charles University [Prague] (CU), Government Medical College Pali, All India Institute of Medical Sciences, National Institute of Biomedical Genomics, Babol University of Medical Sciences, Ufa Eye Research Institute, ondon School of Hygiene & Tropical Medicine, Service d'Ophtalmologie (CHU de Dijon), Centre Hospitalier Universitaire de Dijon - Hôpital François Mitterrand (CHU Dijon), Centre des Sciences du Goût et de l'Alimentation [Dijon] (CSGA), Université de Bourgogne (UB)-AgroSup Dijon - Institut National Supérieur des Sciences Agronomiques, de l'Alimentation et de l'Environnement-Centre National de la Recherche Scientifique (CNRS)-Institut National de Recherche pour l’Agriculture, l’Alimentation et l’Environnement (INRAE), Université Bourgogne Franche-Comté [COMUE] (UBFC), Employee State Insurance Post Graduate Institute of Medical Sciences and Research, University of Waterloo [Waterloo], Federal Polytechnic School of Lausanne, University of Minho, University of Adelaide, Singapore Eye Research Institute [Singapore] (SERI), Seoul National University Hospital, Hanoi National University of Education (HNUE), IRCCS San Raffaele Scientific Institute [Milan, Italie], University of Porto, Queen's University [Belfast] (QUB), University of Dammam - Imam Abdulrahman Bin Faisal University, Harvard University, University of Michigan [Ann Arbor], University of Michigan System, University of Gondar, Royal Liverpool University Hospital, Universiti Tunku Abdul Rahman (UTAR), National Autonomous University of Mexico (UNAM), Ministry of Health and Medical Education [Iran] (MOHME), Mahatma Gandhi University of Medical Sciences and Technology, Cairo University - Faculty of Medicine, National Institutes of Health [Bethesda] (NIH), Shahroud University of Medical Sciences, Federal University of Sao Paulo (Unifesp), University of Applied Sciences Ravensburg-Weingarten, University of São Paulo (USP), Datta Meghe Institute of Medical Sciences, University College of London [London] (UCL), Haramaya University, Sankara Nethralaya Medical Research Foundation, The University of Lahore, Indian Institute of Public Health Gandhinagar, Hamdan Bin Mohammed Smart University, University of Georgia, University of Utah, Institution of Public Health Sciences, Jigjiga Universit, University of Veterinary and Animal Sciences, Independent Consultant, The Chinese University of Hong Kong [Hong Kong], Manipal academy of Higher Education, Hamad Bin Khalifa University (HBKU), Yale University [New Haven], University of Ibadan, University of Belgrade [Belgrade], Faculty of Science of the University of Kragujevac, University of Kragujevac, Deakin University, Burwood, Australia, Deakin University [Burwood], University of Hail, Mysore Medical College, Banaras Hindu University [Varanasi] (BHU), Ophtalmologistes Associe Monastir, Qazvin University of Medical Sciences, The University of Sydney, John Paul II Catholic University of Lublin (KUL), Institute of Human Virology [Nigeria] (IHVN), Myungsung Medical College, Centre Hospitalier Universitaire Fattouma Bourguiba, Partenaires INRAE, Baku State University, Health Services Academy, L V Prasad Eye Institute, Health Ministers Council Gulf Cooperative Council Stat, Medical College of Wisconsin [Milwaukee] (MCW), Xiamen University Malaysia, Yonsei University, Oslo Metropolitan University (OsloMet), School of Optometry and Vision Science, UNSW Sydney, Sydney, NSW, Australia, Brien Holden Vision Institute, Fondation Théa, The Fred Hollows Foundation, Bill & Melinda Gates Foundation, Lions Clubs International Foundation, Sightsavers International, and University of Heidelberg., and GBD 2019 Blindness and Vision Impairment Collaborators* on behalf of the Vision Loss Expert Group of the Global Burden of Disease Study.

Subjects
Pediatrics, medicine.medical_specialty, Refractive error, Visual acuity, genetic structures, Eye disease, 030231 tropical medicine, Population, Glaucoma, 03 medical and health sciences, 0302 clinical medicine, medicine, Global health, 030212 general & internal medicine, [SDV.MHEP.OS]Life Sciences [q-bio]/Human health and pathology/Sensory Organs, education, education.field_of_study, business.industry, Articles, General Medicine, Diabetic retinopathy, Macular degeneration, medicine.disease, eye diseases, 3. Good health, medicine.symptom, business
Abstract

Background: Many causes of vision impairment can be prevented or treated. With an ageing global population, the demands for eye health services are increasing. We estimated the prevalence and relative contribution of avoidable causes of blindness and vision impairment globally from 1990 to 2020. We aimed to compare the results with the World Health Assembly Global Action Plan (WHA GAP) target of a 25% global reduction from 2010 to 2019 in avoidable vision impairment, defined as cataract and undercorrected refractive error. Methods: We did a systematic review and meta-analysis of population-based surveys of eye disease from January, 1980, to October, 2018. We fitted hierarchical models to estimate prevalence (with 95% uncertainty intervals [UIs]) of moderate and severe vision impairment (MSVI; presenting visual acuity from

Published
2021
Full Text
View/download PDF

15. Phase 3, Randomized, 20-Month Study of the Efficacy and Safety of Bimatoprost Implant in Patients with Open-Angle Glaucoma and Ocular Hypertension (ARTEMIS 2)

Author

Bacharach, J., Tatham, A., Ferguson, G., Belalcazar, S., Thieme, H., Goodkin, M. L., Chen, M. Y., Guo, Q., Liu, J., Robinson, M. R., Bejanian, M., Wirta, D. L., Alezzandrini, A., Bercovich, G., Deromedis, P., Furno Sola, F., Gentile, C., Lerner, S., Lupinacci, A., Zeolite, C., Birt, C., Crichton, A., Gagne, S., Giunta, M., Harasymowycz, P., Jinapriya, D., Nicolela, M., Nixon, D., Saurel, P., Yan, D., Yuen, D., Arango, S., Martinez, A., Parra Restrepo, J. C., Korda, V., Kadlecova, J., Svacinova, J., Khairy, H., El Ibiary, H., El Sanabary, Z., Bell, K., Greslechner, R., Koch, J., Lorenz, K., Oberacher-Velten, I., Schmickler, S., Schuart, C., Bandello, F., Cagini, C., Figus, M., Mastropasqua, L., Rossetti, L., Uva, M. G., Thayanithi, S., Wells, A., Husain, R., Koh, V., Lim, D., Tin, A., Gous, P., Venter, L., Kee, C., Kook, M., Park, K. -H., Eraslan, M., Kayikcioglu, O., Yildirim, N., Bourne, R., Choudhary, A., Cordeiro, F., Dubois, V., Kirwan, J., Lim, S., Martin, K., Nithy, A., Prabhu, A., Amir, A., Barnebey, H., Beck, A., Bergstrom, L., Borisuth, N., Branch, J. D., Briggs, J., Bylsma, S., Chang, P., Christie, W., Cotter, F., Depenbusch, M., Goldberg, D. F., Greiner, J., Gupta, S., Gutmark, R., Han, Y., Heersink, S., Kahook, M., Khouri, A., Kim, J., Kushnick, H., Lin, C., Luchs, J., Maharaj, A., Mansberger, S. L., Mares, F., Miller-Ellis, E., Modi, S., Paul, M., Pitha, I., Saltzmann, R., Sato, M., Savestsky, M., Segal, B., Segal, Z., Serle, J., Sherwood, M., Singh, I., Smith, S. E., Song, J., Sorenson, R., Tenkman, L., Tekwani, N., Tubbs, C., Tyson, F., Vizzeri, G., Vold, S., Vu, Q., Warren, K. S., and Wirta, D.

Subjects
Adult, Male, medicine.medical_specialty, Intraocular pressure, genetic structures, Corneal Touch, Ocular hypertension, Glaucoma, Timolol, Young Adult, Double-Blind Method, Ophthalmology, Clinical endpoint, Humans, Medicine, Pharmacology (medical), Original Research Article, Antihypertensive Agents, Intraocular Pressure, Aged, Aged, 80 and over, Drug Implants, Dose-Response Relationship, Drug, Bimatoprost, business.industry, Middle Aged, medicine.disease, eye diseases, Female, Ocular Hypertension, sense organs, Implant, Ophthalmic Solutions, business, Glaucoma, Open-Angle, medicine.drug
Abstract

Objective To evaluate the intraocular pressure (IOP)-lowering efficacy and safety of 10 and 15 µg bimatoprost implant in patients with open-angle glaucoma (OAG) or ocular hypertension (OHT). Methods This randomized, 20-month, multicenter, masked, parallel-group, phase 3 trial enrolled 528 patients with OAG or OHT and an open iridocorneal angle inferiorly in the study eye. Study eyes were administered 10 or 15 µg bimatoprost implant on day 1, week 16, and week 32, or twice-daily topical timolol maleate 0.5%. Primary endpoints were IOP and IOP change from baseline through week 12. Safety measures included treatment-emergent adverse events (TEAEs) and corneal endothelial cell density (CECD). Results Both 10 and 15 µg bimatoprost implant met the primary endpoint of noninferiority to timolol in IOP lowering through 12 weeks. Mean IOP reductions from baseline ranged from 6.2–7.4, 6.5–7.8, and 6.1–6.7 mmHg through week 12 in the 10 µg implant, 15 µg implant, and timolol groups, respectively. IOP lowering was similar after the second and third implant administrations. Probabilities of requiring no IOP-lowering treatment for 1 year after the third administration were 77.5% (10 µg implant) and 79.0% (15 µg implant). The most common TEAE was conjunctival hyperemia, typically temporally associated with the administration procedure. Corneal TEAEs of interest (primarily corneal endothelial cell loss, corneal edema, and corneal touch) were more frequent with the 15 than the 10 µg implant and generally were reported after repeated administrations. Loss in mean CECD from baseline to month 20 was ~ 5% in 10 µg implant-treated eyes and ~ 1% in topical timolol-treated eyes. Visual field progression (change in the mean deviation from baseline) was reduced in the 10 µg implant group compared with the timolol group. Conclusions The results corroborated the previous phase 3 study of the bimatoprost implant. The bimatoprost implant met the primary endpoint and effectively lowered IOP. The majority of patients required no additional treatment for 12 months after the third administration. The benefit-risk assessment favored the 10 over the 15 µg implant. Studies evaluating other administration regimens with reduced risk of corneal events are ongoing. The bimatoprost implant has the potential to improve adherence and reduce treatment burden in glaucoma. Clinicaltrials.gov Identifier NCT02250651. Supplementary Information The online version contains supplementary material available at 10.1007/s40265-021-01624-9.

Published
2021
Full Text
View/download PDF

16. ANATOMICAL CHANGES BETWEEN ARGUS II RETINAL PROSTHESIS AND INNER RETINAL LAYERS DETECTED BY SPECTRAL DOMAIN OPTICAL COHERENCE TOMOGRAPHY IN FIRST YEAR: A CASE REPORT

Author

Aly Mom, Colombo L, Rossetti L, and Fabio Patelli

Subjects
medicine.medical_specialty, medicine.medical_treatment, retinal prosthesis, Case Report, Spectral domain, 01 natural sciences, Prosthesis, 03 medical and health sciences, chemistry.chemical_compound, 0302 clinical medicine, Optical coherence tomography, retinitis pigmentosa, Ophthalmology, Medicine, epiretinal fibrosis, 0101 mathematics, Close contact, computer.programming_language, Argus, medicine.diagnostic_test, business.industry, 010102 general mathematics, Retinal, General Medicine, eye diseases, chemistry, Retinal Prosthesis, epiretinal prosthesis, 030221 ophthalmology & optometry, Argus II, sense organs, Implant, business, computer
Abstract

This case report describes the formation of thick epiretinal fibrosis in the 1st year after implantation of an Argus II retinal prosthesis in a retinitis pigmentosa patient., Purpose: To report and describe the anatomical changes detected by spectral domain optical coherence tomography between an Argus II retinal prosthesis and the inner retinal layers during 1-year follow-up. Methods and Results: A patient presented with epiretinal fibrosis 12 months after implant of an Argus II epiretinal prosthesis. One month after uneventful surgery in March 2016, an evident hyporeflective space was detected between the epiretinal prosthesis and the inner retinal surface by spectral domain optical coherence tomography. An epiretinal hyperreflective band was noticed during follow-up and 1 year after surgery. Spectral domain optical coherence tomography showed close contact of the band with the array, which greatly increased the electrical threshold of stimulation for most of the electrodes. Some electrodes were no longer functioning. No changes in visual performance were detected. Conclusion: Argus II epiretinal prosthesis implant may be complicated by the formation of a hyperreflective epiretinal band, detectable by spectral domain optical coherence tomography. The band may alter prosthesis function; to date, the patient did not scored any decrease in visual function.

Published
2021
Full Text
View/download PDF

18. Prevalence and causes of vision loss in sub-Saharan Africa in 2015: magnitude, temporal trends and projections

Author

Naidoo, Kovin, Kempen, John H, Gichuhi, Stephen, Braithwaite, Tasanee, Casson, Robert J, Cicinelli, Maria Vittoria, Das, Aditi, Flaxman, Seth R, Jonas, Jost B, Keeffe, Jill Elizabeth, Leasher, Janet, Limburg, Hans, Pesudovs, Konrad, Resnikoff, Serge, Silvester, Alexander J, Tahhan, Nina, Taylor, Hugh R, Wong, Tien Y, Bourne, Rupert R A, Vision Loss Expert Group of the Global Burden of Disease Study. Collaborators (Bourne R, Ackland P, Arditi A, Barkana Y, Bozkurt B, Tasanee B, Bron A, Budenz D, Cai F, Casson R, Chakravarthy U, Choi J, Cicinelli MV, Congdon N, Dana R, Dandona R, Dandona L, Das A, Dekaris I, Monte Del Monte MD, Deva J, Dirani M, Dreer L, Ellwein L, Frazier M, Frick K, Friedman D, Furtado J, Gao H, Gazzard A, George R, Gichuhi S, Gonzalez V, Hammond B, Hartnett ME, He M, Hejtmancik J, Hirai F, Huang J, Ingram A, Javitt J, Jonas J, Joslin C, Keeffe J, Kempen J, Khairallah M, Khanna R, Kim J, Lambrou G, Lansingh VC, Lanzetta P, Leasher J, Lim J, Hans L, Mansouri K, Mathew A, Morse A, Munoz B, Musch D, Naidoo K, Nangia V, Maria P, Battaglia Parodi M, Pena FY, Pesudovs K, Peto T, Quigley H, Raju M, Ramulu P, Resnikoff S, Reza D, Robin A, Rossetti L, Saaddine J, Sandar M, Serle J, Shen T, Shetty R, Sieving P, Silva JC, Silvester A, Sitorus RS, Stambolian D, Stevens G, Taylor H, Tejedor J, Tielsch J, Topouzis F, Tsilimbaris M, Meurs JV, Varma R, Virgili G, Volmink J, Wang YX, Ning-Li Wang SW, Wiedemann P, Wong T, Wormald R, Zheng Y, Flaxman S)., Naidoo, Kovin, Kempen, John H, Gichuhi, Stephen, Braithwaite, Tasanee, Casson, Robert J, Cicinelli, Maria Vittoria, Das, Aditi, Flaxman, Seth R, Jonas, Jost B, Keeffe, Jill Elizabeth, Leasher, Janet, Limburg, Han, Pesudovs, Konrad, Resnikoff, Serge, Silvester, Alexander J, Tahhan, Nina, Taylor, Hugh R, Wong, Tien Y, Bourne, Rupert R A, Vision Loss Expert Group of the Global Burden of Disease Study., Collaborators (Bourne R, Ackland, P, Arditi, A, Barkana, Y, Bozkurt, B, Tasanee, B, Bron, A, Budenz, D, Cai, F, Casson, R, Chakravarthy, U, Choi, J, Cicinelli, Mv, Congdon, N, Dana, R, Dandona, R, Dandona, L, Das, A, Dekaris, I, Monte Del Monte, Md, Deva, J, Dirani, M, Dreer, L, Ellwein, L, Frazier, M, Frick, K, Friedman, D, Furtado, J, Gao, H, Gazzard, A, George, R, Gichuhi, S, Gonzalez, V, Hammond, B, Hartnett, Me, He, M, Hejtmancik, J, Hirai, F, Huang, J, Ingram, A, Javitt, J, Jonas, J, Joslin, C, Keeffe, J, Kempen, J, Khairallah, M, Khanna, R, Kim, J, Lambrou, G, Lansingh, Vc, Lanzetta, P, Leasher, J, Lim, J, Hans, L, Mansouri, K, Mathew, A, Morse, A, Munoz, B, Musch, D, Naidoo, K, Nangia, V, Maria, P, Battaglia Parodi, M, Pena, Fy, Pesudovs, K, Peto, T, Quigley, H, Raju, M, Ramulu, P, Resnikoff, S, Reza, D, Robin, A, Rossetti, L, Saaddine, J, Sandar, M, Serle, J, Shen, T, Shetty, R, Sieving, P, Silva, Jc, Silvester, A, Sitorus, R, Stambolian, D, Stevens, G, Taylor, H, Tejedor, J, Tielsch, J, Topouzis, F, Tsilimbaris, M, Meurs, Jv, Varma, R, Virgili, G, Volmink, J, Wang, Yx, Ning-Li Wang, Sw, Wiedemann, P, Wong, T, Wormald, R, Zheng, Y, and Flaxman, S).

Subjects
Refractive error, medicine.medical_specialty, Sub saharan, Visual acuity, Visual Acuity, Glaucoma, Blindness, Cataract, Macular Degeneration, 03 medical and health sciences, Cellular and Molecular Neuroscience, 0302 clinical medicine, Epidemiology, Prevalence, Humans, Medicine, 030212 general & internal medicine, Africa South of the Sahara, business.industry, public health, Presbyopia, Macular degeneration, Refractive Errors, medicine.disease, Sensory Systems, Ophthalmology, 030221 ophthalmology & optometry, epidemiology, medicine.symptom, business, Visually Impaired Persons, Forecasting, Demography
Abstract

BackgroundThis study aimed to assess the prevalence and causes of vision loss in sub-Saharan Africa (SSA) in 2015, compared with prior years, and to estimate expected values for 2020.MethodsA systematic review and meta-analysis assessed the prevalence of blindness (presenting distance visual acuity In SSA, age-standardised prevalence of blindness, MSVI and MVI in 2015 were 1.03% (80% uncertainty interval (UI) 0.39–1.81), 3.64% (80% UI 1.71–5.94) and 2.94% (80% UI 1.05–5.34), respectively, for male and 1.08% (80% UI 0.40–1.93), 3.84% (80% UI 1.72–6.37) and 3.06% (80% UI 1.07–5.61) for females, constituting a significant decrease since 2010 for both genders. There were an estimated 4.28 million blind individuals and 17.36 million individuals with MSVI; 101.08 million individuals were estimated to have near vision loss due to presbyopia. Cataract was the most common cause of blindness (40.1%), whereas undercorrected refractive error (URE) (48.5%) was the most common cause of MSVI. Sub-Saharan West Africa had the highest proportion of blindness compared with the other SSA subregions.ConclusionsCataract and URE, two of the major causes of blindness and vision impairment, are reversible with treatment and thus promising targets to alleviate vision impairment in SSA.

Published
2020
Full Text
View/download PDF

21. Changes in corneal parameters at confocal microscopy in treated glaucoma patients

Author

Ranno S, Fogagnolo P, Rossetti L, Orzalesi N, and Nucci P

Subjects
Ophthalmology, RE1-994
Abstract

Stefano Ranno1, Paolo Fogagnolo2, Luca Rossetti3, Nicola Orzalesi3, Paolo Nucci11Eye Clinic, San Giuseppe Hospital, University of Milan, Milan, Italy; 2GB Bietti Foundation for Study and Research in Ophthalmology, Rome, Italy; 3Eye Clinic, Department of Medicine, San Paolo Hospital, University of Milan, Milan, ItalyBackground: The purpose of this study was to evaluate corneal parameters in treated glaucoma patients, nontreated glaucoma patients, and normal subjects using confocal microscopy.Methods: Forty patients with primary open-angle glaucoma and 22 untreated controls underwent confocal microscopy of the cornea using the Heidelberg retinal tomograph cornea module. The glaucoma group was divided into two subgroups, ie, patients on medical treatment for at least two years before inclusion (with beta-blockers or prostaglandin analogs) and nontreated glaucoma patients. The following corneal parameters were evaluated: endothelial cell density and number, reflectivity, and tortuosity of sub-basal nerves. For reflectivity and tortuosity, a dedicated grading scale ranging from 0 to 4 was used. Differences between treatments were also evaluated in the treated glaucoma group.Results: Number of fibers and reflectivity of the sub-basal plexus were significantly lower in glaucoma patients as compared with controls (2.5 ± 0.7 versus 2.9 ± 0.9, P = 0.006, and 2.3 ± 0.8 versus 2.7 ± 0.9, P = 0.04, respectively), whereas tortuosity was significantly higher (2.6 ± 1 versus 2.0 ± 0.8, P = 0.007). Endothelial cell density (measured as cells per mm2) was lower in the glaucoma group comparing treated patients with nontreated patients (2826 ± 285 versus 3124 ± 272, P = 0.0003). Comparing treated patients with nontreated patients, relevant differences were found in number (2.3 ± 0.7 versus 2.8 ± 0.8, P = 0.004), tortuosity (2.8 ± 1 versus 2.2 ± 0.8, P = 0.004), and reflectivity (2.2 ± 0.8 versus 2.6 ± 0.8, P = 0.04). No differences in corneal parameters were found between beta-blockers and prostaglandin analogs.Conclusion: This study shows that differences in corneal parameters between glaucoma patients and controls may be due to the medical treatments used for glaucoma. These data should be taken into consideration in long-standing medical glaucoma treatment and in potential candidates for surgery.Keywords: cornea, glaucoma, sub-basal nerves, endothelial cells, confocal microscopy

Published
2011

22. Effective refractive error coverage in adults aged 50 years and older: estimates from population-based surveys in 61 countries

Author

Bourne, RRA, Cicinelli, MV, Sedighi, T, Tapply, IH, McCormick, I, Jonas, JB, Congdon, NG, Ramke, J, Naidoo, KS ; https://orcid.org/0000-0001-8261-9779, Fricke, TR ; https://orcid.org/0000-0001-8087-6835, Burton, MJ, Müller, A, Bikbov, MM, Furtado, JM, Kyari, F, He, M, Wang, YX, Vijaya, L, Nangia, V, Brian, G, Emamian, MH, Fotouhi, A, Hashemi, H, Khandekar, RB, Marmamula, S ; https://orcid.org/0000-0003-1716-9809, Salomão, S, George, R, Kazakbaeva, G, Braithwaite, T, Casson, RJ, Iwase, A, Gupta, N, Abdianwall, MH, Varma, R, Wong, TY, Wang, N, Taylor, HR, Flaxman, SR, Keel, S, Resnikoff, S ; https://orcid.org/0000-0002-5866-4446, Bron, A, Cheng, CY, Fernandes, A, Friedman, D, Gazzard, A, Kahloun, R, Kempen, J, Khairallah, M, Lansingh, VC, Leasher, J, Leveziel, N, Limburg, H, Nowak, M, Pesudovs, K ; https://orcid.org/0000-0002-6322-9369, Peto, T, Rossetti, L, Tahhan, N, Alemayehu, W, Arditi, A, Dana, R, Del Monte, M, Deva, J, Dreer, L, Ehrlich, J, Ellwein, L, Hammond, B, Hartnett, ME, Ingram, A, Khanna, R ; https://orcid.org/0000-0002-8698-5562, Kim, J, Lim, J, Morse, A, Musch, D, Parodi, MB, Ramulu, P, Robin, A, Serle, J, Shen, T, Sitorus, RS, Stambolian, D, Topouzis, F, Tsilimbaris, M, Virgili, G, West, S, Ababora, JK, AlSawahli, H, Andriamanjato, HH, Barrenechea, R, Batlle, JF, Burnett, AM ; https://orcid.org/0000-0003-3772-6625, Finger, RP, Gallarreta, M, Gomez-Bastar, PA, Gurung, R, Jain, E, Kabona, GE, Kalua, K, Kandeke, L, Karimurio, J, Kikira, SA, Bourne, RRA, Cicinelli, MV, Sedighi, T, Tapply, IH, McCormick, I, Jonas, JB, Congdon, NG, Ramke, J, Naidoo, KS ; https://orcid.org/0000-0001-8261-9779, Fricke, TR ; https://orcid.org/0000-0001-8087-6835, Burton, MJ, Müller, A, Bikbov, MM, Furtado, JM, Kyari, F, He, M, Wang, YX, Vijaya, L, Nangia, V, Brian, G, Emamian, MH, Fotouhi, A, Hashemi, H, Khandekar, RB, Marmamula, S ; https://orcid.org/0000-0003-1716-9809, Salomão, S, George, R, Kazakbaeva, G, Braithwaite, T, Casson, RJ, Iwase, A, Gupta, N, Abdianwall, MH, Varma, R, Wong, TY, Wang, N, Taylor, HR, Flaxman, SR, Keel, S, Resnikoff, S ; https://orcid.org/0000-0002-5866-4446, Bron, A, Cheng, CY, Fernandes, A, Friedman, D, Gazzard, A, Kahloun, R, Kempen, J, Khairallah, M, Lansingh, VC, Leasher, J, Leveziel, N, Limburg, H, Nowak, M, Pesudovs, K ; https://orcid.org/0000-0002-6322-9369, Peto, T, Rossetti, L, Tahhan, N, Alemayehu, W, Arditi, A, Dana, R, Del Monte, M, Deva, J, Dreer, L, Ehrlich, J, Ellwein, L, Hammond, B, Hartnett, ME, Ingram, A, Khanna, R ; https://orcid.org/0000-0002-8698-5562, Kim, J, Lim, J, Morse, A, Musch, D, Parodi, MB, Ramulu, P, Robin, A, Serle, J, Shen, T, Sitorus, RS, Stambolian, D, Topouzis, F, Tsilimbaris, M, Virgili, G, West, S, Ababora, JK, AlSawahli, H, Andriamanjato, HH, Barrenechea, R, Batlle, JF, Burnett, AM ; https://orcid.org/0000-0003-3772-6625, Finger, RP, Gallarreta, M, Gomez-Bastar, PA, Gurung, R, Jain, E, Kabona, GE, Kalua, K, Kandeke, L, Karimurio, J, and Kikira, SA

Abstract

Background: In 2021, WHO Member States endorsed a global target of a 40-percentage-point increase in effective refractive error coverage (eREC; with a 6/12 visual acuity threshold) by 2030. This study models global and regional estimates of eREC as a baseline for the WHO initiative. Methods: The Vision Loss Expert Group analysed data from 565 448 participants of 169 population-based eye surveys conducted since 2000 to calculate eREC (met need/[met need + undermet need + unmet need]). A binary logistic regression model was used to estimate eREC by Global Burden of Disease (GBD) Study super region among adults aged 50 years and older. Findings: In 2021, distance eREC was 79·1% (95% CI 72·4–85·0) in the high-income super region; 62·1% (54·7–68·8) in north Africa and Middle East; 49·5% (45·0–54·0) in central Europe, eastern Europe, and central Asia; 40·0% (31·7–48·2) in southeast Asia, east Asia, and Oceania; 34·5% (29·4–40·0) in Latin America and the Caribbean; 9·0% (6·5–12·0) in south Asia; and 5·7% (3·1–9·0) in sub-Saharan Africa. eREC was higher in men and reduced with increasing age. Global distance eREC increased from 2000 to 2021 by 19·0%. Global near vision eREC for 2021 was 20·5% (95% CI 17·8–24·4). Interpretation: Over the past 20 years, distance eREC has increased in each super region yet the WHO target will require substantial improvements in quantity and quality of refractive services in particular for near vision impairment. Funding: WHO, Sightsavers, The Fred Hollows Foundation, Fondation Thea, Brien Holden Vision Institute, Lions Clubs International Foundation.

Published
2022

23. RPE65-Associated Retinopathies in the Italian Population: A Longitudinal Natural History Study

Author

Testa, F., Murro, V., Signorini, S., Colombo, L., Iarossi, G., Parmeggiani, F., Falsini, Benedetto, Salvetti, A. P., Brunetti-Pierri, R., Aprile, G., Bertone, C., Suppiej, A., Romano, Federica, Karali, M., Donati, S., Melillo, P., Sodi, A., Quaranta, L., Rossetti, Lodovico, Buzzonetti, Luca, Chizzolini, M., Rizzo, Stanislao, Staurenghi, G., Banfi, S., Azzolini, Chiara, Simonelli, F., Falsini B. (ORCID:0000-0002-3569-4968), Romano F., Rossetti L., Buzzonetti L. (ORCID:0000-0002-3200-3260), Rizzo S. (ORCID:0000-0001-6302-063X), Azzolini C. (ORCID:0000-0001-7270-577X), Testa, F., Murro, V., Signorini, S., Colombo, L., Iarossi, G., Parmeggiani, F., Falsini, Benedetto, Salvetti, A. P., Brunetti-Pierri, R., Aprile, G., Bertone, C., Suppiej, A., Romano, Federica, Karali, M., Donati, S., Melillo, P., Sodi, A., Quaranta, L., Rossetti, Lodovico, Buzzonetti, Luca, Chizzolini, M., Rizzo, Stanislao, Staurenghi, G., Banfi, S., Azzolini, Chiara, Simonelli, F., Falsini B. (ORCID:0000-0002-3569-4968), Romano F., Rossetti L., Buzzonetti L. (ORCID:0000-0002-3200-3260), Rizzo S. (ORCID:0000-0001-6302-063X), and Azzolini C. (ORCID:0000-0001-7270-577X)

Abstract

PURPOSE. To investigate the course of inherited retinal degenerations (IRD) due to mutations in the RPE65 gene. METHODS. This longitudinal multicentric retrospective chart-review study was designed to collect best corrected visual acuity (BCVA), Goldman visual field, optical coherence tomography (OCT), and electroretinography (ERG) measurements. The data, including imaging, were collected using an electronic clinical research form and were reviewed at a single center to improve consistency. RESULTS. From an overall cohort of 60 Italian patients with RPE65-associated IRD, 43 patients (mean age, 27.8 ± 19.7 years) were included and showed a mean BCVA of 2.0 ± 1.0 logMAR. Time-to-event analysis revealed a median age of 33.8 years and 41.4 years to reach low vision and blindness based on BCVA, respectively. ERG (available for 34 patients) showed undetectable responses in most patients (26; 76.5%). OCT (available for 31 patients) revealed epiretinal membranes in five patients (16.1%). Central foveal thickness significantly decreased with age at a mean annual rate of −0.6%/y (P = 0.044). We identified 43 different variants in the RPE65 gene in the entire cohort. Nine variants were novel. Finally, to assess genotype-phenotype correlations, patients were stratified according to the number of RPE65 loss-of-function (LoF) alleles. Patients without LoF variants showed significantly (P < 0.05) better BCVA compared to patients with one or two LoF alleles. CONCLUSIONS. We described the natural course of RPE65-associated IRD in an Italian cohort showing for the first time a specific genotype-phenotype association. Our findings can contribute to a better management of RPE65-associated IRD patients.

Published
2022

25. Correction to: Switching to Preservative-Free Tafluprost/Timolol Fixed-Dose Combination in the Treatment of Open-Angle Glaucoma or Ocular Hypertension: Subanalysis of Data from the VISIONARY Study According to Baseline Monotherapy Treatment (Advances in Therapy, (2022), 39, 8, (3501-3521), 10.1007/s12325-022-02166-6)

Author

Oddone, F., Kirwan, J., Lopez-Lopez, F., Zimina, M., Fassari, C., Hollo, G., Faschinger, C., Chen, E., Nemeth, G., Bator, G., Tsorbatzoglou, A., Acs, T., Ferencz, M., Sohajda, Z., Toth, J., Volner, V., Vogt, G., Biro, Z., Facsko, A., Nemes, J., Berta, A., Elek, I., Ng, E., Rossi, G., Rossetti, L., Vetrugno, M., Iester, M., Marchini, G., Scorcia, V., Staurenghi, G., Cagini, C., Salgarello, T., Bettin, P., Figus, M., Scuderi, G. L., De Cilla, S., Grundmane, I., Linavska, N., Volksone, L., Laganovska, G., Baumane, K., Lemij, H., Gundersen, K. G., Erichev, V., Adbulaeva, E., Karlova, E., Zakharova, E., Panova, I., Malyugin, B., Rodriguez-Agirretxe, I., Valladares, A. M., del Castillo, J. B., Gimenez, R., Vallejo, M. P., Garcia-Medina, J. J., Lopez, A. A., Torregrosa, S., Loscos, J., Kolko, M., Ansari, E., Broadway, D., Claridge, K., Ruben, S., Nita, A., Smith, M., Moosavi, A., King, A. J. W., and Kinsella, M.

Subjects
Pharmacology (medical), General Medicine
Abstract

The authors would like to acknowledge missing data for all prior latanoprost users as a whole. The following sentence has been added to the manuscript (page 8, first paragraph): Mean (SD) reduction from baseline at Month 6 for users of all latanoprost formulations (preserved and PF) was 6.1 (4.25) mmHg (25.9%; p\0.0001). The authors have also prepared a table to summarise the change in intraocular pressure following a switch to the preservative-free tafluprost/timolol fixed-dose combination from all latanoprost formulations (preserved and preservative-free formulations). See Table 1 below.(Table Preseneted.) .The original article has been corrected.

Published
2022
Full Text
View/download PDF

27. Switching to Preservative-Free Tafluprost/Timolol Fixed-Dose Combination in the Treatment of Open-Angle Glaucoma or Ocular Hypertension: Subanalysis of Data from the VISIONARY Study According to Baseline Monotherapy Treatment

Author

Oddone, F., Kirwan, J., Lopez-Lopez, F., Zimina, M., Fassari, C., Hollo, G., Faschinger, C., Chen, E., Nemeth, G., Bator, G., Tsorbatzoglou, A., Acs, T., Ferencz, M., Sohajda, Z., Toth, J., Volner, V., Vogt, G., Biro, Z., Facsko, A., Nemes, J., Berta, A., Elek, I., Ng, E., Rossi, G., Rossetti, L., Vetrugno, M., Iester, M., Marchini, G., Scorcia, V., Staurenghi, G., Cagini, C., Salgarello, T., Bettin, P., Figus, M., Scuderi, G. L., De Cilla, S., Grundmane, I., Linavska, N., Volksone, L., Laganovska, G., Baumane, K., Lemij, H., Gundersen, K. G., Erichev, V., Adbulaeva, E., Karlova, E., Zakharova, E., Panova, I., Malyugin, B., Rodriguez-Agirretxe, I., Valladares, A. M., del Castillo, J. B., Gimenez, R., Vallejo, M. P., Garcia-Medina, J. J., Lopez, A. A., Torregrosa, S., Loscos, J., Kolko, M., Ansari, E., Broadway, D., Claridge, K., Ruben, S., Nita, A., Smith, M., Moosavi, A., King, A. J. W., and Kinsella, M.

Subjects
Adult, Hyperemia, Tafluprost/timolol fixed-dose combination, Ocular hypertension, VISIONARY study, Travoprost, Preservative-free topical medication, Prostaglandin analogue monotherapy, Humans, Pharmacology (medical), Prospective Studies, Chronic, Open-angle glaucoma, Antihypertensive Agents, Intraocular Pressure, Real-world evidence, Prostaglandins A, Fatigue Syndrome, Chronic, Prostaglandins F, Glaucoma, General Medicine, Beta-blocker monotherapy, Fatigue Syndrome, Drug Combinations, Bimatoprost, Open-Angle, Timolol, Latanoprost, Glaucoma, Open-Angle
Abstract

Introduction: The VISIONARY study demonstrated statistically significant intraocular pressure (IOP) reductions with the preservative-free fixed-dose combination of tafluprost 0.0015% and timolol 0.5% (PF tafluprost/timolol FC) in open-angle glaucoma (OAG) or ocular hypertension (OHT) patients, sub-optimally controlled with topical prostaglandin analogue (PGA) or beta-blocker monotherapy. Current subanalyses have examined these data according to the baseline monotherapy. Methods: A European, prospective, observational study included adults (aged ≥ 18 years) with OAG or OHT, who were switched to the PF tafluprost/timolol FC from PGA or beta-blocker monotherapy. Treatment outcomes were reported according to prior monotherapy subgroup: beta-blocker, preserved latanoprost, PF-latanoprost, bimatoprost, tafluprost, and travoprost. Endpoints included the mean change from baseline regarding IOP, conjunctival hyperemia, and corneal fluorescein staining (CFS) at Week 4 and Week 12, and at Month 6. Results: The subanalysis included 577 patients. All prior monotherapy subgroups demonstrated statistically significant IOP reductions from baseline at Week 4, that were maintained through Month 6 (p

Published
2022
Full Text
View/download PDF

29. Treatment of Open-Angle Glaucoma and Ocular Hypertension with Preservative-Free Tafluprost/Timolol Fixed-Dose Combination Therapy: The VISIONARY Study

Author

Oddone, F., Tanga, L., Kothy, P., Hollo, G., Faschinger, C., Chen, E., Nemeth, G., Bator, G., Tsorbatzoglou, A., Acs, T., Ferencz, M., Sohajda, Z., Toth, J., Volner, V., Vogt, G., Biro, Z., Facsko, A., Nemes, J., Berta, A., Elek, I., Ng, E., Rossi, G., Rossetti, L., Vetrugno, M., Iester, M., Marchini, G., Scorcia, V., Staurenghi, G., Cagini, C., Salgarello, T., Bettin, P., Figus, M., Scuderi, G. L., De Cilla, S., Grundmane, I., Linavska, N., Volksone, L., Laganovska, G., Baumane, K., Lemij, H., Gundersen, K. G., Zimina, M., Erichev, V., Karlova, E., Zakharova, E., Panova, I., Malyugin, B., Aguirrec, I. R., Lopez-Lopez, F., Valladares, A. M., del Castillo, J. B., Gimenez, R., Vallejo, M. P., Medina, J. G., Lopez, A. A., Torregrosa, S., Loscos, J., Kolko, M., Ansari, E., Broadway, D., Claridge, K., Ruben, S., Kirwan, J., Nita, A., Smith, M., Moosavi, A., King, A. J. W., and Kinsella, M.

Subjects
Male, 030213 general clinical medicine, Intraocular pressure, genetic structures, Ocular hypertension, Timolol, Glaucoma, 0302 clinical medicine, Prostaglandins, Synthetic, Medicine, Pharmacology (medical), Prospective Studies, Open-angle glaucoma, media_common, Original Research, Aged, 80 and over, Fixed-dose combination, General Medicine, Middle Aged, Drug Combinations, Tolerability, 030220 oncology & carcinogenesis, Female, Glaucoma, Open-Angle, medicine.drug, medicine.medical_specialty, medicine.drug_class, Tonometry, Ocular, 03 medical and health sciences, Preservative-free topical medication, Ophthalmology, Humans, media_common.cataloged_instance, European union, Antihypertensive Agents, Intraocular Pressure, Aged, business.industry, Preservatives, Pharmaceutical, Prostaglandins F, Tafluprost, Correction, medicine.disease, eye diseases, sense organs, Prostaglandin analogue, business
Abstract

Introduction: A non-interventional, multicenter, European, prospective evaluation of the effectiveness, tolerability, and safety of a topical preservative-free tafluprost (0.0015%) and timolol (0.5%) fixed-dose combination (PF tafluprost/timolol FC) in adults with open-angle glaucoma (OAG) and ocular hypertension (OHT) demonstrating insufficient response to topical beta-receptor blockers or prostaglandin analogue (PGA) monotherapy. Methods: Mean intraocular pressure (IOP) change from baseline was measured at study visits following a switch to PF tafluprost/timolol FC. Primary endpoint was absolute mean IOP change at month 6. Change from baseline concerning ocular signs and symptoms was also explored. Results: Analyses included 577 patients (59.6% female). Mean age (SD) was 67.8 (11.67) years. Mean (SD) IOP reduction from baseline was significant at all study visits; 5.4 (3.76) mmHg (23.7%) at week 4, 5.9 (3.90) mmHg (25.6%) at week 12, and 5.7 (4.11) mmHg (24.9%) at month 6 (p < 0.0001 for all visits). At month 6, 69.2%, 53.6%, 40.0%, and 25.8% were responders based on ≥ 20%, ≥ 25%, ≥ 30%, and ≥ 35% cutoff values for mean IOP, respectively. Significant reductions were observed concerning corneal fluorescein staining (p < 0.0001), dry eye symptoms, irritation, itching, and foreign body sensation (p < 0.001 for each parameter). Conjunctival hyperemia was significantly reduced at all study visits (p < 0.0001 at each visit). Overall, 69 treatment-related adverse events (AEs) were reported, one of which was serious (status asthmaticus). Most AEs were mild to moderate in severity, and the majority had resolved or were resolving at the end of the study period. Conclusion: In clinical practice, PF tafluprost/timolol FC provided statistically and clinically significant IOP reductions in patients with OAG and OHT insufficiently controlled on or intolerant to PGA or beta-receptor blocker monotherapy. The full IOP reduction appeared at week 4 and was maintained over the 6-month study period. Key symptoms of ocular surface health improved. Trial Registration: European Union electronic Register of Post-Authorisation Studies (EU PAS) register number, EUPAS22204.

Published
2020
Full Text
View/download PDF

32. What can we learn from systematic segmental analysis of fetal heart by postmortem micro-CT: Is it time to change approach?

Author

Sandrini, C., primary, Lombardi, C.M., additional, Zambelli, V., additional, Zanarotti, R., additional, Raffaelli, R., additional, Franchi, M.P., additional, Papadopoulos, N., additional, Di Pace, C., additional, Hoxha, S., additional, Murari, A., additional, Chamitava, L., additional, Zanolin, M.E., additional, Faggian, G., additional, Ribichini, F.L., additional, Rossetti, L., additional, and Luciani, G.B., additional

Published
2021
Full Text
View/download PDF

33. Neural Conduction Along Postretinal Visual Pathways in Glaucoma

Author

Oddone, F, Rossetti, L, Parravano, M, Sbardella, D, Coletta, M, Ziccardi, L, Roberti, G, Carnevale, C, Romano, D, Manni, G, and Parisi, V

Subjects
Aging, medicine.medical_specialty, genetic structures, PERG, Cognitive Neuroscience, Nerve fiber layer, Glaucoma, Neurosciences. Biological psychiatry. Neuropsychiatry, Visual system, 03 medical and health sciences, chemistry.chemical_compound, 0302 clinical medicine, Ophthalmology, Settore MED/30, medicine, OCT imaging, Original Research, Neural Conduction, business.industry, Retinal, medicine.disease, visual pathways, eye diseases, Visual field, medicine.anatomical_structure, glaucoma, chemistry, Retinal ganglion cell, 030221 ophthalmology & optometry, Analysis of variance, sense organs, business, VEP, 030217 neurology & neurosurgery, RC321-571, Neuroscience
Abstract

Purpose: This study was conducted in order to evaluate retinal ganglion cell (RCG) function and the neural conduction along the postretinal large and small axons and its correlation with retinal nerve fiber layer thickness (RNFL-T) in open-angle glaucoma (OAG) eyes.Methods: Thirty-seven OAG patients (mean age: 51.68 ± 9.83 years) with 24–2 Humphrey mean deviation (MD) between −2.5 and −20 dB and IOP Results: In the OAG group, a significant (ANOVA, p < 0.01) reduction of 60′ and 15′ PERG P50-N95 and VEP N75-P100 amplitudes and of RNFL-T [overall (average of all quadrants) or temporal] with respect to controls was found; the values of 60′ and 15′ PERG P50 and VEP P100 implicit times and of retinocortical time (RCT; difference between VEP P100 and PERG P50 implicit times) were significantly (p < 0.01) increased with respect to control ones. The observed increased RCTs were significantly linearly correlated (Pearson’s test, p < 0.01) with the reduced PERG amplitude and MD values, whereas no significant linear correlation (p < 0.01) with RNFL-T (overall or temporal) values was detected.Conclusions: In OAG, there is an impaired postretinal neural conduction along both large and small axons (increased 60′ and 15′ RCTs) that is related to RGC dysfunction, but independent from the RNFL morphology. This implies that, in OAG, the impairment of postretinal neural structures can be electrophysiologically identified and may contribute to the visual field defects, as suggested by the linear correlation between the increase of RCT and MD reduction.

Published
2021

34. Differential effects of hypothalamic long-chain fatty acid infusions on suppression of hepatic glucose production

Author

Ross, R.A., Rossetti, L., Lam, T.K.T., and Schwartz, G.J.

Subjects
Cellular signal transduction -- Research, Diabetes -- Genetic aspects, Diabetes -- Care and treatment, Diabetes -- Research, Saturated fatty acids -- Physiological aspects, Saturated fatty acids -- Genetic aspects, Saturated fatty acids -- Research, Biological sciences
Abstract

Our objective was to investigate whether the direct bilateral infusion of the monounsaturated fatty acid (MUFA) oleic acid (OA) within the mediobasal hypothalamus (MBH) is sufficient to reproduce the effect of administration of OA (30 nmol) in the third cerebral ventricle, which inhibits glucose production (GP) in rats. We used the pancreatic basal insulin clamp technique (plasma insulin ~20 mU/ml) in combination with tracer dilution methodology to compare the effect of MBH OA on GP to that of a saturated fatty acid (SFA), palmitic acid (PA), and a polyunsaturated fatty acid (PUFA), linoleic acid (LA). The MBH infusion of 200 but not 40 pmol of OA was sufficient to markedly inhibit GP (by 61% from 12.6 [+ or -] 0.6 to 5.1 [+ or -] 1.6 mg x [kg.sup.-1] x [min.sup.-1]) such that exogenous glucose had to be infused at the rate of 6.0 [+ or -] 1.2 mg x [kg.sup.-1] x [min.sup.-1] to prevent hypoglycemia. MBH infusion of PA also caused a significant decrease in GP, but only at a total dose of 4 nmol (GP 5.8 [+ or -] 1.6 mg x [kg.sup.-1] x [min.sup.-1]). Finally, MBH LA at a total dose of 0.2 and 4 nmol failed to modify GP compared with rats receiving MBH vehicle. Increased availability of OA within the MBH is sufficient to markedly inhibit GP. LA does not share the effect of OA, whereas PA can reproduce the potent effect of OA on GP, but only at a higher dose. It remains to be determined whether SFAs need to be converted to MUFAs to exert this effect or whether they activate a separate signaling pathway to inhibit GP. nutrient sensing; diabetes; obesity; central nervous system doi: 10.1152/ajpendo.00190.2010.

Published
2010

36. Author Correction: Visual field loss and vision-related quality of life in the Italian Primary Open Angle Glaucoma Study

Author

Rulli, Eliana, Quaranta, Luciano, Riva, Ivano, Poli, Davide, Hollander, Lital, Galli, Fabio, Katsanos, Andreas, Oddone, Francesco, Torri, Valter, Weinreb, N Varano L, Robert, Carchedi, T, Talarico, S, Frezzotti, P, Parravano, F, Motolese, I, Bagaglia, Sa, Rossi, Gcm, Lateri, S, Bossolesi, L, Carmassi, L, Rolle, T, Piccini, R, Ratiglia, R, Rossi, A, Gandolfi, S, Tagliavini, V, Ungaro, N, Fossarello, M, Cucca, A, Zucca, I, Uva, M, Bonacci, E, Cardarella, G, Tognetto, D, Vattovani, O, Vallon, P, Iannacone, F, Fontana, L, Marchi, S, Manni, Gl, Jannetta, D, Roberti, G, Rossetti, L, Maggiolo, E, Oneta, O, Sborgia, C, Cantatore, F, Mastropasqua, L, Agnifili, L, Campos, E, Gizzi, C, Giannaccare, G, Pucci, V, Cassamali, M, Costagliola, C, Traverso, C, Scotto, R, Musolino, M, Landi, L, Bagnis, A., Rulli, Eliana, Quaranta, Luciano, Riva, Ivano, Poli, Davide, Hollander, Lital, Galli, Fabio, Katsanos, Andrea, Oddone, Francesco, Torri, Valter, Weinreb, Robert, N Varano L, Carchedi, T, Talarico, S, Frezzotti, P, Parravano, F, Motolese, I, Bagaglia, Sa, Rossi, Gcm, Lateri, S, Bossolesi, L, Carmassi, L, Rolle, T, Piccini, R, Ratiglia, R, Rossi, A, Gandolfi, S, Tagliavini, V, Ungaro, N, Fossarello, M, Cucca, A, Zucca, I, Uva, M, Bonacci, E, Cardarella, G, Tognetto, D, Vattovani, O, Vallon, P, Iannacone, F, Fontana, L, Marchi, S, Manni, Gl, Jannetta, D, Roberti, G, Rossetti, L, Maggiolo, E, Oneta, O, Sborgia, C, Cantatore, F, Mastropasqua, L, Agnifili, L, Campos, E, Gizzi, C, Giannaccare, G, Pucci, V, Cassamali, M, Costagliola, C, Traverso, C, Scotto, R, Musolino, M, Landi, L, and Bagnis, A.

Subjects
Multidisciplinary, Open angle glaucoma, business.industry, Published Erratum, lcsh:R, MEDLINE, lcsh:Medicine, Italian Study Group on QoL in Glaucoma, Eye, Quality of life (healthcare), Medicine, Optometry, lcsh:Q, Visual field loss, business, lcsh:Science
Abstract

An amendment to this paper has been published and can be accessed via a link at the top of the paper.

Published
2020

38. Vision-related quality of life and symptom perception change over time in newly-diagnosed primary open angle glaucoma patients

Author

Riva, I, Legramandi, L, Rulli, E, Konstas, Ag, Katsanos, A, Oddone, F, Weinreb, Rn, Quaranta, L, Varano, L, Carchedi, T, Talarico, S, Parravano, F, Motolese, I, Bagaglia, Sa, Rossi, Gcm, Lateri, S, Bossolesi, L, Carmassi, L, Rolle, T, Piccini, R, Ratiglia, R, Rossi, A, Gandolfi, S, Tagliavini, Ungaro, N, Fossarello, M, Cuccu, A, Zucca, I, Uva, M, Bonacci, E, Cardarella, G, Tognetto, D, Vattovani, O, Vallon, P, Iannacone, F, Fontana, L, Marchi, S, Manni, G, Iannetta, D, Roberti, G, Rossetti, L, Maggiolo, E, Oneta, O, Sborgia, C, Cantatore, F, Mastropasqua, L, Agnifili, L, Campos, E, Gizzi, C, Giannaccare, G, Pucci, Cassamali, M, Costagliola, C, Traverso, C, Scotto, R, Musolino, M, Landi, L, Bagnis, A, Riva I, Legramandi L, Rulli E, Konstas AG, Katsanos A, Oddone F, Weinreb RN, Quaranta L, Italian Study Group on QoL in Glaucoma: L Varano, T Carchedi, S Talarico, F Parravano, I Motolese, SA Bagaglia, GCM Rossi, S Lateri, L Bossolesi, L Carmassi, T Rolle, R Piccini, R Ratiglia, A Rossi, S Gandolfi, V Tagliavini, N Ungaro, M Fossarello, A Cuccu, I Zucca, M Uva, E Bonacci, G Cardarella, D Tognetto, O Vattovani, P Vallon, F Iannacone, L Fontana, S Marchi, GL Manni, D Jannetta, G Roberti, L Rossetti, E Maggiolo, O Oneta, C Sborgia, F Cantatore, L Mastropasqua, L Agnifili, E Campos, C Gizzi, G Giannaccare, V Pucci, M Cassamali, C Costagliola, C Traverso, R Scotto, M Musolino, L Landi, A Bagnis, Riva, Ivano, Legramandi, Lorenzo, Rulli, Eliana, Konstas, Anastasios G, Katsanos, Andrea, Oddone, Francesco, Weinreb, Robert N, Quaranta, Luciano, Varano, L, Carchedi, T, Talarico, S, Parravano, F, Motolese, I, Bagaglia, Sa, Rossi, Gcm, Lateri, S, Bossolesi, L, Carmassi, L, Rolle, T, Piccini, R, Ratiglia, R, Rossi, A, Gandolfi, S, Tagliavini, Ungaro, N, Fossarello, M, Cuccu, A, Zucca, I, Uva, M, Bonacci, E, Cardarella, G, Tognetto, D, Vattovani, O, Vallon, P, Iannacone, F, Fontana, L, Marchi, S, Manni, Gl, Jannetta, D, Roberti, G, Rossetti, L, Maggiolo, E, Oneta, O, Sborgia, C, Cantatore, F, Mastropasqua, L, Agnifili, L, Campos, E, Gizzi, C, Giannaccare, G, Pucci, Cassamali, M, Costagliola, C, Traverso, C, Scotto, R, Musolino, M, Landi, L, and Bagnis, A.

Subjects
0301 basic medicine, Change over time, medicine.medical_specialty, Aging, Visual acuity, Open angle glaucoma, genetic structures, Population, lcsh:Medicine, Glaucoma, Diseases, Italian Study Group on QoL in Glaucoma, Neurodegenerative, Eye, Article, 03 medical and health sciences, Medical research, 0302 clinical medicine, Quality of life, Clinical Research, Settore MED/30, Internal medicine, medicine, POAG, lcsh:Science, education, Prospective cohort study, Author Correction, Eye Disease and Disorders of Vision, education.field_of_study, Multidisciplinary, business.industry, lcsh:R, Neurosciences, medicine.disease, primary open angle glaucoma, humanities, eye diseases, 030104 developmental biology, Symptom perception, glaucoma, quality of life, lcsh:Q, sense organs, medicine.symptom, business, 030217 neurology & neurosurgery
Abstract

To evaluate the change over time of vision-related quality of life (QoL) and glaucoma symptoms in a population of newly-diagnosed primary open angle glaucoma (POAG) patients. Multicenter, prospective study. Consecutive newly-diagnosed POAG patients were enrolled and followed-up for one year. Follow-up visits were scheduled at 6 and 12 months from baseline. At each visit, vision-related QoL and glaucoma-related symptoms were assessed by the means of the 25-item National Eye Institute Visual Function Questionnaire (NEI-VFQ-25) and the Glaucoma Symptom Scale (GSS), respectively. Trends over time for NEI-VFQ-25 and GSS scores were evaluated with longitudinal linear mixed models. One-hundred seventy-eight patients were included in the analysis. At baseline, early to moderate glaucoma stages were associated with higher scores for most GSS and NEI-VFQ-25 items, while lower best-corrected visual acuity was associated with lower scores for 4 of the 12 NEI-VFQ-25 items. During the follow-up, all the GSS scores, the NEI-VFQ-25 total score, and 7 of the 12 NEI-VFQ-25 scores significantly improved (p

Published
2019

39. Practical recommendations for measuring rates of visual field change in glaucoma

Author

Chauhan, B.C., Garway-Heath, D.F., Goni, F.J., Rossetti, L., Bengtsson, B., Viswanathan, A.C., and Heijl, A.

Subjects
Visual fields -- Physiological aspects, Perimetry -- Methods, Perimetry -- Research, Glaucoma -- Diagnosis, Glaucoma -- Development and progression, Glaucoma -- Research, Health
Published
2008

40. Causes of blindness and vision impairment in 2020 and trends over 30 years, and prevalence of avoidable blindness in relation to VISION 2020: the Right to Sight: an analysis for the Global Burden of Disease Study

Author

Steinmetz, JD, Bourne, RRA, Briant, PS, Flaxman, S, Taylor, HR, Jonas, JB, Abdoli, A, Abrha, WA, Abualhasan, A, Abu-Gharbieh, E, Adal, TG, Afshin, A, Ahmadieh, H, Alemayehu, W, Alemzadeh, SA, Alfaar, AS, Alipour, V, Androudi, S, Arabloo, J, Arditi, A, Aregawi, BB, Arrigo, A, Ashbaugh, C, Ashrafi, E, Atnafu, DD, Bagli, E, Baig, AA, Barnighausen, TW, Parodi, MB, Beheshti, M, Bhagavathula, AS, Bhardwaj, N, Bhardwaj, P, Bhattacharyya, K, Bijani, A, Bikbov, M, Bottone, M, Braithwaite, T, Bron, AM, Nagaraja, SB, Butt, ZA, dos Santos, FLC, Carneiro, VLA, Casson, RJ, Cheng, C-Y, Choi, J-YJ, Chu, D-T, Cicinelli, MV, Coelho, JM, Congdon, NG, Couto, RAS, Cromwell, EA, Dahlawi, SMA, Dai, X, Dana, R, Dandona, L, Dandona, R, Del Monte, MA, Molla, MD, Dervenis, N, Desta, AA, Deva, JP, Diaz, D, Djalalinia, S, Ehrlich, JR, Elayedath, R, Elhabashy, HR, Ellwein, LB, Emamian, MH, Eskandarieh, S, Farzadfar, F, Fernandes, AG, Fischer, F, Friedman, DS, Furtado, JM, Gaidhane, S, Gazzard, G, Gebremichael, B, George, R, Ghashghaee, A, Gilani, SA, Golechha, M, Hamidi, S, Hammond, BR, Hartnett, MER, Hartono, RK, Hashi, A, Hay, S, Hayat, K, Heidari, G, Ho, HC, Holla, R, Househ, M, Huang, JJ, Ibitoye, SE, Ilic, IM, Ilic, MD, Ingram, AD, Irvani, SSN, Islam, SMS, Itumalla, R, Jayaram, S, Jha, RP, Kahloun, R, Kalhor, R, Kandel, H, Kasa, AS, Kavetskyy, T, Kayode, GA, Kempen, JH, Khairallah, M, Khalilov, R, Khan, EA, Khanna, RC, Khatib, MN, Khoja, TAM, Kim, GR, Kim, JE, Kim, YJ, Kisa, A, Kisa, S, Kosen, S, Koyanagi, A, Bicer, BK, Kulkarni, V, Kurmi, OP, Landires, I, Lansingh, VC, Leasher, JL, LeGrand, KE, Leveziel, N, Limburg, H, Liu, X, Kunjathur, SM, Maleki, S, Manafi, N, Mansouri, K, McAlinden, C, Meles, GG, Mersha, AM, Michalek, IM, Miller, TR, Misra, S, Mohammad, Y, Mohammadi, SF, Mohammed, JA, Mokdad, AH, Moni, MA, Al Montasir, A, Morse, AR, Mulaw, GF, Naderi, M, Naderifar, H, Naidoo, KS, Naimzada, MD, Nangia, V, Swamy, SN, Naveed, M, Negash, H, Huong, LTN, Nunez-Samudio, V, Ogbo, FA, Ogundimu, K, Olagunju, AT, Onwujekwe, OE, Otstavnov, N, Owolabi, MO, Pakshir, K, Panda-Jonas, S, Parekh, U, Park, E-C, Pasovic, M, Pawar, S, Pesudovs, K, Peto, T, Pham, HQ, Pinheiro, M, Podder, V, Rahimi-Movaghar, V, Rahman, MHU, Ramulu, PY, Rathi, P, Rawaf, DL, Rawaf, S, Rawal, L, Reinig, N, Renzaho, AMN, Rezapour, A, Robin, AL, Rossetti, L, Sabour, S, Safi, S, Sahebkar, A, Sahraian, MA, Samy, AM, Sathian, B, Saya, GK, Saylan, M, Shaheen, AA, Shaikh, MA, Shen, TT, Shibuya, K, Shiferaw, WS, Shigematsu, M, Shin, JI, Silva, JC, Silvester, A, Singh, JA, Singhal, D, Sitorus, RS, Skiadaresi, E, Skryabin, VY, Skryabina, AA, Soheili, A, Sorrie, MB, Sousa, RARC, Sreeramareddy, CT, Stambolian, D, Tadesse, EG, Tahhan, N, Tareque, MI, Topouzis, F, Bach, XT, Tsegaye, GW, Tsilimbaris, MK, Varma, R, Virgili, G, Vongpradith, A, Vu, GT, Wang, YX, Wang, N, Weldemariam, AH, West, SK, Wondmeneh, TG, Wong, TY, Yaseri, M, Yonemoto, N, Yu, C, Zastrozhin, MS, Zastrozhina, A, Zhang, Z-J, Zimsen, SRM, Resnikoff, S, Vos, T, Steinmetz, JD, Bourne, RRA, Briant, PS, Flaxman, S, Taylor, HR, Jonas, JB, Abdoli, A, Abrha, WA, Abualhasan, A, Abu-Gharbieh, E, Adal, TG, Afshin, A, Ahmadieh, H, Alemayehu, W, Alemzadeh, SA, Alfaar, AS, Alipour, V, Androudi, S, Arabloo, J, Arditi, A, Aregawi, BB, Arrigo, A, Ashbaugh, C, Ashrafi, E, Atnafu, DD, Bagli, E, Baig, AA, Barnighausen, TW, Parodi, MB, Beheshti, M, Bhagavathula, AS, Bhardwaj, N, Bhardwaj, P, Bhattacharyya, K, Bijani, A, Bikbov, M, Bottone, M, Braithwaite, T, Bron, AM, Nagaraja, SB, Butt, ZA, dos Santos, FLC, Carneiro, VLA, Casson, RJ, Cheng, C-Y, Choi, J-YJ, Chu, D-T, Cicinelli, MV, Coelho, JM, Congdon, NG, Couto, RAS, Cromwell, EA, Dahlawi, SMA, Dai, X, Dana, R, Dandona, L, Dandona, R, Del Monte, MA, Molla, MD, Dervenis, N, Desta, AA, Deva, JP, Diaz, D, Djalalinia, S, Ehrlich, JR, Elayedath, R, Elhabashy, HR, Ellwein, LB, Emamian, MH, Eskandarieh, S, Farzadfar, F, Fernandes, AG, Fischer, F, Friedman, DS, Furtado, JM, Gaidhane, S, Gazzard, G, Gebremichael, B, George, R, Ghashghaee, A, Gilani, SA, Golechha, M, Hamidi, S, Hammond, BR, Hartnett, MER, Hartono, RK, Hashi, A, Hay, S, Hayat, K, Heidari, G, Ho, HC, Holla, R, Househ, M, Huang, JJ, Ibitoye, SE, Ilic, IM, Ilic, MD, Ingram, AD, Irvani, SSN, Islam, SMS, Itumalla, R, Jayaram, S, Jha, RP, Kahloun, R, Kalhor, R, Kandel, H, Kasa, AS, Kavetskyy, T, Kayode, GA, Kempen, JH, Khairallah, M, Khalilov, R, Khan, EA, Khanna, RC, Khatib, MN, Khoja, TAM, Kim, GR, Kim, JE, Kim, YJ, Kisa, A, Kisa, S, Kosen, S, Koyanagi, A, Bicer, BK, Kulkarni, V, Kurmi, OP, Landires, I, Lansingh, VC, Leasher, JL, LeGrand, KE, Leveziel, N, Limburg, H, Liu, X, Kunjathur, SM, Maleki, S, Manafi, N, Mansouri, K, McAlinden, C, Meles, GG, Mersha, AM, Michalek, IM, Miller, TR, Misra, S, Mohammad, Y, Mohammadi, SF, Mohammed, JA, Mokdad, AH, Moni, MA, Al Montasir, A, Morse, AR, Mulaw, GF, Naderi, M, Naderifar, H, Naidoo, KS, Naimzada, MD, Nangia, V, Swamy, SN, Naveed, M, Negash, H, Huong, LTN, Nunez-Samudio, V, Ogbo, FA, Ogundimu, K, Olagunju, AT, Onwujekwe, OE, Otstavnov, N, Owolabi, MO, Pakshir, K, Panda-Jonas, S, Parekh, U, Park, E-C, Pasovic, M, Pawar, S, Pesudovs, K, Peto, T, Pham, HQ, Pinheiro, M, Podder, V, Rahimi-Movaghar, V, Rahman, MHU, Ramulu, PY, Rathi, P, Rawaf, DL, Rawaf, S, Rawal, L, Reinig, N, Renzaho, AMN, Rezapour, A, Robin, AL, Rossetti, L, Sabour, S, Safi, S, Sahebkar, A, Sahraian, MA, Samy, AM, Sathian, B, Saya, GK, Saylan, M, Shaheen, AA, Shaikh, MA, Shen, TT, Shibuya, K, Shiferaw, WS, Shigematsu, M, Shin, JI, Silva, JC, Silvester, A, Singh, JA, Singhal, D, Sitorus, RS, Skiadaresi, E, Skryabin, VY, Skryabina, AA, Soheili, A, Sorrie, MB, Sousa, RARC, Sreeramareddy, CT, Stambolian, D, Tadesse, EG, Tahhan, N, Tareque, MI, Topouzis, F, Bach, XT, Tsegaye, GW, Tsilimbaris, MK, Varma, R, Virgili, G, Vongpradith, A, Vu, GT, Wang, YX, Wang, N, Weldemariam, AH, West, SK, Wondmeneh, TG, Wong, TY, Yaseri, M, Yonemoto, N, Yu, C, Zastrozhin, MS, Zastrozhina, A, Zhang, Z-J, Zimsen, SRM, Resnikoff, S, and Vos, T

Abstract

BACKGROUND: Many causes of vision impairment can be prevented or treated. With an ageing global population, the demands for eye health services are increasing. We estimated the prevalence and relative contribution of avoidable causes of blindness and vision impairment globally from 1990 to 2020. We aimed to compare the results with the World Health Assembly Global Action Plan (WHA GAP) target of a 25% global reduction from 2010 to 2019 in avoidable vision impairment, defined as cataract and undercorrected refractive error. METHODS: We did a systematic review and meta-analysis of population-based surveys of eye disease from January, 1980, to October, 2018. We fitted hierarchical models to estimate prevalence (with 95% uncertainty intervals [UIs]) of moderate and severe vision impairment (MSVI; presenting visual acuity from <6/18 to 3/60) and blindness (<3/60 or less than 10° visual field around central fixation) by cause, age, region, and year. Because of data sparsity at younger ages, our analysis focused on adults aged 50 years and older. FINDINGS: Global crude prevalence of avoidable vision impairment and blindness in adults aged 50 years and older did not change between 2010 and 2019 (percentage change -0·2% [95% UI -1·5 to 1·0]; 2019 prevalence 9·58 cases per 1000 people [95% IU 8·51 to 10·8], 2010 prevalence 96·0 cases per 1000 people [86·0 to 107·0]). Age-standardised prevalence of avoidable blindness decreased by -15·4% [-16·8 to -14·3], while avoidable MSVI showed no change (0·5% [-0·8 to 1·6]). However, the number of cases increased for both avoidable blindness (10·8% [8·9 to 12·4]) and MSVI (31·5% [30·0 to 33·1]). The leading global causes of blindness in those aged 50 years and older in 2020 were cataract (15·2 million cases [9% IU 12·7-18·0]), followed by glaucoma (3·6 million cases [2·8-4·4]), undercorrected refractive error (2·3 million cases [1·8-2·8]), age-related macular degeneration (1·8 million cases [1·3-2·4]), and diabetic retinopathy (0·86 mill

Published
2021

41. Trends in prevalence of blindness and distance and near vision impairment over 30 years: an analysis for the Global Burden of Disease Study

Author

Bourne, RRA, Steinmetz, JD, Flaxman, S, Briant, PS, Taylor, HR, Resnikoff, S, Casson, RJ, Abdoli, A, Abu-Gharbieh, E, Afshin, A, Ahmadieh, H, Akalu, Y, Alamneh, AA, Alemayehu, W, Alfaar, AS, Alipour, V, Anbesu, EW, Androudi, S, Arabloo, J, Arditi, A, Asaad, M, Bagli, E, Baig, AA, Barnighausen, TW, Parodi, MB, Bhagavathula, AS, Bhardwaj, N, Bhardwaj, P, Bhattacharyya, K, Bijani, A, Bikbov, M, Bottone, M, Braithwaite, T, Bron, AM, Butt, ZA, Cheng, C-Y, Chu, D-T, Cicinelli, MV, Coelho, JM, Dagnew, B, Dai, X, Dana, R, Dandona, L, Dandona, R, Del Monte, MA, Deva, JP, Diaz, D, Djalalinia, S, Dreer, LE, Ehrlich, JR, Ellwein, LB, Emamian, MH, Fernandes, AG, Fischer, F, Friedman, DS, Furtado, JM, Gaidhane, AM, Gaidhane, S, Gazzard, G, Gebremichael, B, George, R, Ghashghaee, A, Golechha, M, Hamidi, S, Hammond, BR, Hartnett, MER, Hartono, RK, Hay, S, Heidari, G, Ho, HC, Chi, LH, Househ, M, Ibitoye, SE, Ilic, IM, Ilic, MD, Ingram, AD, Irvani, SSN, Jha, RP, Kahloun, R, Kandel, H, Kasa, AS, Kempen, JH, Keramati, M, Khairallah, M, Khan, EA, Khanna, RC, Khatib, MN, Kim, JE, Kim, YJ, Kisa, A, Kisa, S, Koyanagi, A, Kurmi, OP, Lansingh, VC, Leasher, JL, Leveziel, N, Limburg, H, Majdan, M, Manafi, N, Mansouri, K, McAlinden, C, Mohammadi, SF, Mohammadian-Hafshejani, A, Mohammadpourhodki, R, Mokdad, AH, Moosavi, D, Morse, AR, Naderi, M, Naidoo, KS, Nangia, V, Cuong, TN, Huong, LTN, Ogundimu, K, Olagunju, AT, Ostroff, SM, Panda-Jonas, S, Pesudovs, K, Peto, T, Syed, ZQ, Rahman, MHU, Ramulu, PY, Rawaf, DL, Rawaf, S, Reinig, N, Robin, AL, Rossetti, L, Safi, S, Sahebkar, A, Samy, AM, Saxena, D, Serle, JB, Shaikh, MA, Shen, TT, Shibuya, K, Shin, JI, Silva, JC, Silvester, A, Singh, JA, Singhal, D, Sitorus, RS, Skiadaresi, E, Skirbekk, V, Soheili, A, Sousa, RARC, Spurlock, EE, Stambolian, D, Taddele, BW, Tadesse, EG, Tahhan, N, Tareque, MI, Topouzis, F, Bach, XT, Travillian, RS, Tsilimbaris, MK, Varma, R, Virgili, G, Wang, N, Wang, YX, West, SK, Wong, TY, Zaidi, Z, Zewdie, KA, Jonas, JB, Vos, T, Bourne, RRA, Steinmetz, JD, Flaxman, S, Briant, PS, Taylor, HR, Resnikoff, S, Casson, RJ, Abdoli, A, Abu-Gharbieh, E, Afshin, A, Ahmadieh, H, Akalu, Y, Alamneh, AA, Alemayehu, W, Alfaar, AS, Alipour, V, Anbesu, EW, Androudi, S, Arabloo, J, Arditi, A, Asaad, M, Bagli, E, Baig, AA, Barnighausen, TW, Parodi, MB, Bhagavathula, AS, Bhardwaj, N, Bhardwaj, P, Bhattacharyya, K, Bijani, A, Bikbov, M, Bottone, M, Braithwaite, T, Bron, AM, Butt, ZA, Cheng, C-Y, Chu, D-T, Cicinelli, MV, Coelho, JM, Dagnew, B, Dai, X, Dana, R, Dandona, L, Dandona, R, Del Monte, MA, Deva, JP, Diaz, D, Djalalinia, S, Dreer, LE, Ehrlich, JR, Ellwein, LB, Emamian, MH, Fernandes, AG, Fischer, F, Friedman, DS, Furtado, JM, Gaidhane, AM, Gaidhane, S, Gazzard, G, Gebremichael, B, George, R, Ghashghaee, A, Golechha, M, Hamidi, S, Hammond, BR, Hartnett, MER, Hartono, RK, Hay, S, Heidari, G, Ho, HC, Chi, LH, Househ, M, Ibitoye, SE, Ilic, IM, Ilic, MD, Ingram, AD, Irvani, SSN, Jha, RP, Kahloun, R, Kandel, H, Kasa, AS, Kempen, JH, Keramati, M, Khairallah, M, Khan, EA, Khanna, RC, Khatib, MN, Kim, JE, Kim, YJ, Kisa, A, Kisa, S, Koyanagi, A, Kurmi, OP, Lansingh, VC, Leasher, JL, Leveziel, N, Limburg, H, Majdan, M, Manafi, N, Mansouri, K, McAlinden, C, Mohammadi, SF, Mohammadian-Hafshejani, A, Mohammadpourhodki, R, Mokdad, AH, Moosavi, D, Morse, AR, Naderi, M, Naidoo, KS, Nangia, V, Cuong, TN, Huong, LTN, Ogundimu, K, Olagunju, AT, Ostroff, SM, Panda-Jonas, S, Pesudovs, K, Peto, T, Syed, ZQ, Rahman, MHU, Ramulu, PY, Rawaf, DL, Rawaf, S, Reinig, N, Robin, AL, Rossetti, L, Safi, S, Sahebkar, A, Samy, AM, Saxena, D, Serle, JB, Shaikh, MA, Shen, TT, Shibuya, K, Shin, JI, Silva, JC, Silvester, A, Singh, JA, Singhal, D, Sitorus, RS, Skiadaresi, E, Skirbekk, V, Soheili, A, Sousa, RARC, Spurlock, EE, Stambolian, D, Taddele, BW, Tadesse, EG, Tahhan, N, Tareque, MI, Topouzis, F, Bach, XT, Travillian, RS, Tsilimbaris, MK, Varma, R, Virgili, G, Wang, N, Wang, YX, West, SK, Wong, TY, Zaidi, Z, Zewdie, KA, Jonas, JB, and Vos, T

Abstract

BACKGROUND: To contribute to the WHO initiative, VISION 2020: The Right to Sight, an assessment of global vision impairment in 2020 and temporal change is needed. We aimed to extensively update estimates of global vision loss burden, presenting estimates for 2020, temporal change over three decades between 1990-2020, and forecasts for 2050. METHODS: We did a systematic review and meta-analysis of population-based surveys of eye disease from January, 1980, to October, 2018. Only studies with samples representative of the population and with clearly defined visual acuity testing protocols were included. We fitted hierarchical models to estimate 2020 prevalence (with 95% uncertainty intervals [UIs]) of mild vision impairment (presenting visual acuity ≥6/18 and <6/12), moderate and severe vision impairment (<6/18 to 3/60), and blindness (<3/60 or less than 10° visual field around central fixation); and vision impairment from uncorrected presbyopia (presenting near vision

Published
2021

42. Dancing With Parkinson's Disease: The SI-ROBOTICS Study Protocol

Author

Bevilacqua, R., Benadduci, M., Bonfigli, A. R., Riccardi, G. R., Melone, G., La Forgia, A., Macchiarulo, N., Rossetti, L., Marzorati, Mauro, Rizzo, G., Di Bitonto, P., Potenza, A., Fiorini, L., Cortellessa Loizzo, F. G., La Viola, C., Cavallo, F., Leone, A., Rescio, G., Caroppo, A., Manni, A., Cesta, A., Cortellessa, G., Fracasso, F., Orlandini, A., Umbrico, A., Rossi, L., Maranesi, E., Marzorati M. (ORCID:0000-0003-1093-2162), Bevilacqua, R., Benadduci, M., Bonfigli, A. R., Riccardi, G. R., Melone, G., La Forgia, A., Macchiarulo, N., Rossetti, L., Marzorati, Mauro, Rizzo, G., Di Bitonto, P., Potenza, A., Fiorini, L., Cortellessa Loizzo, F. G., La Viola, C., Cavallo, F., Leone, A., Rescio, G., Caroppo, A., Manni, A., Cesta, A., Cortellessa, G., Fracasso, F., Orlandini, A., Umbrico, A., Rossi, L., Maranesi, E., and Marzorati M. (ORCID:0000-0003-1093-2162)

Abstract

Introduction: Parkinson's disease (PD) is one of the most frequent causes of disability among older people, characterized by motor disorders, rigidity, and balance problems. Recently, dance has started to be considered an effective exercise for people with PD. In particular, Irish dancing, along with tango and different forms of modern dance, may be a valid strategy to motivate people with PD to perform physical activity. The present protocol aims to implement and evaluate a rehabilitation program based on a new system called “SI-ROBOTICS,” composed of multiple technological components, such as a social robotic platform embedded with an artificial vision setting, a dance-based game, environmental and wearable sensors, and an advanced AI reasoner module. Methods and Analysis: For this study, 20 patients with PD will be recruited. Sixteen therapy sessions of 50 min will be conducted (two training sessions per week, for 8 weeks), involving two patients at a time. Evaluation will be primarily focused on the acceptability of the SI-ROBOTICS system. Moreover, the analysis of the impact on the patients' functional status, gait, balance, fear of falling, cardio-respiratory performance, motor symptoms related to PD, and quality of life, will be considered as secondary outcomes. The trial will start in November 2021 and is expected to end by April 2022. Discussions: The study aims to propose and evaluate a new approach in PD rehabilitation, focused on the use of Irish dancing, together with a new technological system focused on helping the patient perform the dance steps and on collecting kinematic and performance parameters used both by the physiotherapist (for the evaluation and planning of the subsequent sessions) and by the system (to outline the levels of difficulty of the exercise). Ethics and Dissemination: The study was approved by the Ethics Committee of the IRCCS INRCA. It was recorded in ClinicalTrials.gov on the number NCT05005208. The study findings will be used

Published
2021

44. Direct costs of glaucoma and severity of the disease: a multinational long term study of resource utilisation in Europe

Author

Traverso, C.E., Walt, J.G., Kelly, S.P., Hommer, A.H., Bron, A.M., Denis, P., Nordmann, J.-P., Renard, J.-P., Bayer, A., Grehn, F., Pfeiffer, N., Cedrone, C., Gandolfi, S., Orzalesi, N., Nucci, C., Rossetti, L., Azuara-Blanco, A., Bagnis, A., Hitchings, R., Salmon, J.F., Bricola, G., Buchholz, P.M., Kotak, S.V., Katz, L.M., Siegartel, L.R., and Doyle, J.J.

Subjects
Open-angle glaucoma -- Care and treatment, Medical care, Cost of -- Research, Long-term care of the sick -- Economic aspects, Health
Published
2005

48. Lower blood glucose, hyperglucagonemia, and pancreatic [alpha] cell hyperplasia in glucagon receptor knockout mice

Author

Gelling, R.W., Du, X.Q., Dichmann, D.S., Romer, J., Huang, H., Cui, L., Obici, S., Tang, B., Holst, J.J., Fledelius, C., Johansen, P.B., Rossetti, L., Jelicks, L.A., Serup, P., Nishimura, E., and Charron, M.J.

Subjects
Cytochemistry -- Research, Mice, mutant strains -- Usage, Blood sugar -- Physiological aspects, Glucagon -- Physiological aspects, Pancreas -- Physiological aspects, Homeostasis -- Research, Hyperplasia -- Physiological aspects, Islands of Langerhans -- Physiological aspects, Bioenergetics -- Research, Energy metabolism, Body composition -- Research, Science and technology
Abstract

Glucagon, the counter-regulatory hormone to insulin, is secreted from pancreatic [alpha] cells in response to low blood glucose. To examine the role of glucagon in glucose homeostasis, mice were generated with a null mutation of the glucagon receptor ([Gcgr.sup.-/-]). These mice display lower blood glucose levels throughout the day and improved glucose tolerance but similar insulin levels compared with control animals. [Gcgr.sup.-/-] mice displayed supraphysiological glucagon levels associated with postnatal enlargement of the pancreas and hyperplasia of islets due predominantly to [alpha] cell, and to a lesser extent, [delta] cell proliferation. In addition, increased proglucagon expression and processing resulted in increased pancreatic glucogen-like peptide 1 (GLP-1) (1-37) and GLP-1 amide (1-36 amide) content and a 3- to 10-fold increase in circulating GLP-1 amide. [Gcgr.sup.-/-] mice also displayed reduced adiposity and leptin levels but normal body weight, food intake, and energy expenditure. These data indicate that glucagon is essential for maintenance of normal glycemia and postnatal regulation of islet and [alpha] and [delta] cell numbers. Furthermore, the lean phenotype of [Gcgr.sup.-/-] mice suggests glucagon action may be involved in the regulation of whole body composition.

Published
2003

Catalog

Books, media, physical & digital resources
See catalog results